The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0712 GMT - Eurofins Scientific's 2027 target of an improvement in profitability seems firmly within reach, but this is no longer enough as the debate among investors shifts back to growth, Bernstein analysts say in a research note. The French lab-testing company has historically delivered sustainable organic sales growth above 6%, but its growth engine now appears structurally weaker, the analysts say. Eurofins is heavily exposed to Europe, where clinical and research-and-development activity remains weak, and this might explain why organic growth in its biopharma business has remained subdued for the past two years, they add. Bernstein cuts its recommendation on Eurofins stock to market perform from outperform, and trims its target price to 73.90 euros from 77.20 euros. Shares fall 2.1% to 77.08 euros. (adria.calatayud@wsj.com)

0702 GMT - Praram 9 Hospital likely offers value-for-money to upper-middle-tier income segment in Thailand, ttb wealth securities' Siriporn Arunothai says in a research report. It has continued to increase and upgrade its service complexity to narrow gap with peers, while pricing its services 15%-20% below them, the analyst says. Also, its new or expanding services over 2026-2027 include new operating theater, automated peritoneal dialysis, and biplane angiography system. The brokerage projects Praram 9 Hospital's EPS growth at 11.1% and 9.1% in 2027 and 2028, respectively. It raises the stock's target price to 23.80 baht from 21.00 baht to reflect a valuation roll-over, with unchanged buy rating. Shares are unchanged at 19.30 baht. (ronnie.harui@wsj.com)

0631 GMT - Fresenius Medical Care has made progress on its cost-savings plan, but it might need to return to U.S. volume growth to win over investors, Berenberg analysts say in a research note. The German dialysis specialist has delivered around 920 million euros in savings out of a target of 1.2 billion euros while reducing debt, the analysts say. However, U.S. treatment volumes are weak and deteriorated so far this year after being flat in 2025, they add. This will increasingly drive earnings and investors need evidence of positive U.S. treatment growth for shares to move higher, according to Berenberg. Berenberg cuts its recommendation on Fresenius Medical Care stock to hold from buy, while cutting its target price to 42 euros from 60 euros. Shares closed at 40.48 euros on Monday. (adria.calatayud@wsj.com)

0548 GMT - AstraZeneca's agreement with Summit Therapeutics will help the U.K. drugmaker broaden its immuno-oncology portfolio without going all-in, RBC Capital Markets analysts say in a research note. AstraZeneca is investing $2 billion in the Miami-based biotech and entering into a research collaboration centered on ivonescimab, Summit's experimental cancer drug that blocks two proteins--called PD-1 and VEGF--that help tumors grow and evade the immune system. AstraZeneca's investments in this space lacked a so-called PD-1xVEGF asset like ivonescimab, RBC says. Each company retains its development and commercial rights for their assets, which likely signals AstraZeneca believes its own approaches are superior to PD-1xVEGF, the analysts say. Nevertheless, the deal leaves the door open for a potential expansion with Summit in the future, they add. (adria.calatayud@wsj.com)

0402 GMT - Dr. Reddy's Laboratories' North America revenue is expected to trough this fiscal year, supported by the potential U.S. launch of abatacept biosimilar and the resumption of semaglutide supplies in Canada, Citi Research's Vivek Agrawal says in a note. At the same time, improving growth in India, other emerging markets and Europe is driving a favorable shift in business mix toward more sustainable earnings streams, the U.S. bank says. Citi raises its rating on the stock to buy from sell. The bank increases its target price to 1,450 rupees from 1,040 rupees, reflecting improving earnings visibility, strong execution in non-U.S. markets and potential margin expansion. Shares are 1.5% higher at 1,240.75 rupees. (kosaku.narioka@wsj.com; @kosakunarioka)

0257 GMT - Chugai Pharmaceutical's mid-to late-stage pipeline is looking increasingly thin, Jefferies analysts say in a note. Roche has discontinued development of GYM329 for obesity and returned the rights to Chugai. Investors have historically afforded Chugai a premium valuation because of its track record of discovering and developing innovative drugs, the U.S. bank says. Roche's decision diminishes expectations for one of the company's most closely watched pipeline assets, the bank says. Investors may now be less willing to pay the premium multiples that the stock has historically commanded, the bank says. Jefferies cuts its target price on the stock to 6,100 yen from Y8,000. Shares are 2.5% lower at Y6,203. (kosaku.narioka@wsj.com; @kosakunarioka)

0212 GMT - Malaysia's fiscal support could be doing the heavy lifting in sustaining consumer spending despite weaker sentiment, with private consumption growing 4.8% on year in 2Q, Hong Leong IB analyst Jonathan Ooi says in a note. The coming budget due Oct. 9 could extend support, alongside a possible minimum-wage increase, he reckons. Government utilities subsidies and potential cash aid should help consumer sentiment recover, while tourism provides another growth driver, he says. The return of F1 to Sepang during China's Golden Week could be a strong catalyst, he adds. Costs remain a key watch point, with fuel, freight, CPO and coffee prices rising amid the Iran war, Ooi says. Hong Leong maintains an overweight rating on Malaysia's consumer sector. AEON Co. (M) and Focus Point are its top picks. (yingxian.wong@wsj.com)

2345 GMT - Australian stocks look set to edge higher as investors wait on what is widely expected to be a resumption of interest-rate rises by the country's central bank. ASX futures are up by less than 0.1% ahead of Tuesday's session, suggesting that the S&P/ASX 200 benchmark index could lightly add to its week-opening 0.2% rise. Economists and traders expect the Reserve Bank to raise the cash rate by 25 basis points later Tuesday. Ahead of the open, REA Group said it had agreed to buy a 35% stake in an Ireland-based counterpart. Cochlear said it would defend a class action representing shareholders aggrieved at its profit forecasting over its last fiscal year. (stuart.condie@wsj.com)

1339 GMT - Roche Holding has financial room for more deals, CFO Alan Hippe tells investors at a company event in London. The Swiss drugmaker deployed 18.2 billion Swiss francs to deals between 2022 and 2025, and its net debt remained broadly stable, its finance chief says. "The financial flexibility for us is roughly 5 to 7 billion [francs] to do M&A without increasing the debt level," Hippe says. Shares fall 1.3%.